Management of anticoagulation in patients with brain metastasis

2.

Khorana

AA

,

Mackman

N

,

Falanga

A

, et al.

Cancer-associated venous thromboembolism

.

Nat Rev Dis Primers

.

2022

;

8

(

1

):

11

.

3.

Zwicker

JI

,

Liebman

HA

,

Neuberg

D

, et al.

Tumor-derived tissue factor- bearing microparticles are associated with venous thromboembolic events in malignancy

.

Clin Cancer Res

.

2009

;

15

(

22

):

6830

-

6840

.

4.

Geddings

JE

,

Mackman

N.

Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients

.

Blood

.

2013

;

122

(

11

):

1873

-

1880

.

5.

Riedl

J

,

Preusser

M

,

Nazari

PM

, et al.

Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism

.

Blood

.

2017

;

129

(

13

):

1831

-

1839

.

6.

Lyman

GH

,

Carrier

M

,

Ay

C

, et al.

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

.

Blood Adv

.

2021

;

5

(

4

):

927

-

974

.

7.

Key

NS

,

Khorana

AA

,

Kuderer

NM

, et al.

Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update

.

J Clin Oncol

.

2023

;

41

(

16

):

3063

-

3071

.

8.

Donato

J

,

Campigotto

F

,

Uhlmann

EJ

, et al.

Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study

.

Blood

.

2015

;

126

(

4

):

494

-

499

.

9.

Bhambhvani

HP

,

Granucci

M

,

Rodrigues

A

,

Kakusa

BW

,

Hayden Gephart

M.

The primary sites leading to brain metastases: shifting trends at a tertiary care center

.

J Clin Neurosci

.

2020

;

80

:

121

-

124

.

10.

Giustozzi

M

,

Proietti

G

,

Becattini

C

,

Roila

F

,

Agnelli

G

,

Mandalà

M.

ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis

.

Blood Adv

.

2022

;

6

(

16

):

4873

-

4883

.

11.

Ostrowski

RP

,

He

Z

,

Pucko

EB

,

Matyja

E.

Hemorrhage in brain tumor—an unresolved issue

.

Brain Hemorrhages

.

2022

;

3

(

2

):

98

-

102

.

12.

Raskob

GE

,

van Es

N

,

Verhamme

P

, et al;

Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism

.

N Engl J Med

.

2018

;

378

(

7

):

615

-

624

.

13.

Young

AM

,

Marshall

A

,

Thirlwall

J

, et al.

Comparison of an oral factor XA inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)

.

J Clin Oncol

.

2018

;

36

(

20

):

2017

-

2023

.

14.

Agnelli

G

,

Becattini

C

,

Meyer

G

, et al;

Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer

.

N Engl J Med

.

2020

;

382

(

17

):

1599

-

1607

.

15.

McBane

RD II

,

Wysokinski

WE

,

Le-Rademacher

JG

, et al.

Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial

.

J Thromb Haemost

.

2020

;

18

(

2

):

411

-

421

.

16.

Bura-Rivière

A

,

Brisot

D

,

Chatellier

G

, et al;

CASTA DIVA Trial Investigators. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial

.

Chest

.

2022

;

161

(

3

):

781

-

790

.

17.

Schrag

D

,

Uno

H

,

Rosovsky

R

, et al;

CANVAS Investigators. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial

.

JAMA

.

2023

;

329

(

22

):

1924

-

1933

.

18.

Sørensen

HT

,

Pedersen

L

,

van Es

N

,

Büller

HR

,

Horváth-Puhó

E.

Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study

.

Lancet Reg Health Eur

.

2023

;

34

:

100739

.

19.

Carney

BJ

,

Uhlmann

EJ

,

Puligandla

M

, et al.

Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors

.

J Thromb Haemost

.

2019

;

17

(

1

):

72

-

76

.

20.

Leader

A

,

Hamulyák

EN

,

Carney

BJ

, et al.

Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases

.

Blood Adv

.

2020

;

4

(

24

):

6291

-

6297

.

21.

Hamulyák

EN

,

Wang

TF

,

Baumann Kreuziger

L

, et al.

Intracranial hemorrhage in patients with brain metastases receiving anticoagulation (ABC study)

.

Res Pract Thromb Haemost

. Volume

7

, Supplement 2,

100611

,

October

2023

.

22.

Iyengar

V

,

Agrawal

S

,

Chiasakul

T

, et al.

Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review

.

J Thromb Haemost

.

2024

;

22

(

2

):

423

-

429

.

23.

Galgani

A

,

Palleria

C

,

Iannone

LF

, et al.

Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs

.

Front Neurol

.

2018

;

9

:

1067

.

24.

Goldstein

R

,

Rabkin

N

,

Buchman

N

, et al.

The effect of levetiracetam compared with enzyme-inducing antiseizure medications on apixaban and rivaroxaban peak plasma concentrations

.

CNS Drugs

.

2024

;

38

(

5

):

399

-

408

.

25.

Greenberg

SM

,

Ziai

WC

,

Cordonnier

C

, et al;

American Heart Association/American Stroke Association

.

2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association

.

Stroke

.

2022

;

53

(

7

):

e282

-

e361

.

26.

Lesueur

P

,

Kao

W

,

Leconte

A

, et al.

Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial

.

BMC Cancer

.

2020

;

20

(

1

):

147

.

27.

McKenzie

G

,

Gaskins

J

,

Rattani

A

, et al.

Radiosurgery fractionation and post-treatment hemorrhage development for intact melanoma brain metastases

.

J Neurooncol

.

2022

;

160

(

3

):

591

-

599

.

28.

Zoga

E

,

Wolff

R

,

Ackermann

H

, et al.

Factors associated with hemorrhage of melanoma brain metastases after stereotactic radiosurgery in the era of targeted/immune checkpoint inhibitor therapies

.

Cancers (Basel)

.

2022

;

14

(

10

).

29.

Kim

SS

,

Kim

SM

,

Park

M

,

Suh

SH

,

Ahn

SJ

.

Clinico-radiological features of brain metastases from thyroid cancer

.

Medicine (Baltimore)

.

2021

;

100

(

48

):

e28069

.

30.

Pouessel

D

,

Culine

S.

High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor

.

Eur Urol

.

2008

;

53

(

2

):

376

-

381

.

31.

Chevreau

C

,

Ravaud

A

,

Escudier

B

, et al;

French Group on Renal Cancer. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases

.

Clin Genitourin Cancer

.

2014

;

12

(

1

):

50

-

54

.

32.

Mantia

C

,

Uhlmann

EJ

,

Puligandla

M

,

Weber

GM

,

Neuberg

D

,

Zwicker

JI

.

Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin

.

Blood

.

2017

;

129

(

25

):

3379

-

3385

.

33.

Mangieri

A

,

Gallo

F

,

Sticchi

A

, et al.

Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective

.

Cardiovasc Interv Ther

.

2020

;

35

(

2

):

117

-

129

.

34.

Firnhaber

JM

,

Powell

CS

.

Lower extremity peripheral artery disease: diagnosis and treatment

.

Am Fam Physician

.

2019

;

99

(

6

):

362

-

369

.

35.

Sandercock

PA

,

Counsell

C

,

Tseng

MC

,

Cecconi

E.

Oral antiplatelet therapy for acute ischaemic stroke

.

Cochrane Database Syst Rev

.

2014

;

2014

(

3

):

CD000029

.

36.

Cea Soriano

L

,

Gaist

D

,

Soriano-Gabarró

M

,

Bromley

S

,

García Rodríguez

LA

.

Low-dose aspirin and risk of intracranial bleeds: an observational study in UK general practice

.

Neurology

.

2017

;

89

(

22

):

2280

-

2287

.

37.

Miller

EJ

,

Patell

R

,

Uhlmann

EJ

, et al.

Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors

.

Blood Adv

.

2022

;

6

(

5

):

1559

-

1565

.

38.

Xiao

B

,

Wang

W

,

Zhang

D.

Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials

.

Onco Targets Ther

.

2018

;

11

:

5059

-

5074

.

39.

Norden

AD

,

Bartolomeo

J

,

Tanaka

S

, et al.

Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients

.

J Neurooncol

.

2012

;

106

(

1

):

121

-

125

.

40.

Chang

SH

,

Chou

IJ

,

Yeh

YH

, et al.

Association between use of non– vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation

.

JAMA

.

2017

;

318

(

13

):

1250

-

1259

.

41.

Wang

TF

,

Baumann Kreuziger

L

,

Leader

A

, et al.

Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies—TacDOAC registry: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy

.

J Thromb Haemost

.

2021

;

19

(

8

):

2068

-

2081

.

42.

Verso

M

,

Munoz

A

,

Bauersachs

R

, et al.

Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

.

Eur J Cancer

.

2021

;

148

:

371

-

381

.

43.

Ehret

F

,

Kaul

D

,

Mose

L

, et al.

Intracranial hemorrhage in patients with anticoagulant therapy undergoing stereotactic radiosurgery for brain metastases: a bi-institutional analysis

.

Cancers (Basel)

.

2022

;

14

(

3

):

465

.

44.

Seiffge

DJ

,

Wilson

D

,

Ambler

G

, et al.

Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants

.

J Neurol Neurosurg Psychiatry

.

2021

;

92

(

8

):

805

-

814

.

45.

Ghia

AJ

,

Tward

JD

,

Anker

CJ

,

Boucher

KM

,

Jensen

RL

,

Shrieve

DC

.

Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control

.

J Radiosurg SBRT

.

2014

;

3

(

1

):

43

-

50

.

46.

Carney

BJ

,

Uhlmann

EJ

,

Puligandla

M

, et al.

Anticoagulation after intracranial hemorrhage in brain tumors: risk of recurrent hemorrhage and venous thromboembolism

.

Res Pract Thromb Haemost

.

2020

;

4

(

5

):

860

-

865

.

47.

Hsu

C

,

Patell

R

,

Zwicker

JI

.

The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis

.

Blood Adv

.

2023

;

7

(

17

):

4721

-

4727

.

48.

Patell

R

,

Hsu

C

,

Shi

M

, et al.

Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer

.

Haematologic

a.

2023

;

109

(

6

):

0

.

49.

Ianosi

B

,

Gaasch

M

,

Rass

V

, et al.

Early thrombosis prophylaxis with enoxaparin is not associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage

.

Eur J Neurol

.

2019

;

26

(

2

):

333

-

341

.

50.

Faust

AC

,

Finch

CK

,

Hurdle

AC

,

Elijovich

L.

Early versus delayed initiation of pharmacological venous thromboembolism prophylaxis after an intracranial hemorrhage

.

Neurologist

.

2017

;

22

(

5

):

166

-

170

.

51.

Kirkilesis

G

,

Kakkos

SK

,

Bicknell

C

,

Salim

S

,

Kakavia

K.

Treatment of distal deep vein thrombosis

.

Cochrane Database Syst Rev

.

2020

;

4

(

4

):

CD013422

.

52.

Bikdeli

B

,

Caraballo

C

,

Trujillo-Santos

J

, et al;

RIETE Investigators. Clinical presentation and short- and long-term outcomes in patients with isolated distal deep vein thrombosis vs proximal deep vein thrombosis in the RIETE registry

.

JAMA Cardiol

.

2022

;

7

(

8

):

857

-

865

.

53.

Le Gal

G

,

Kovacs

MJ

,

Bertoletti

L

, et al;

SSPE Investigators. Risk for recurrent venous thromboembolism in patients with subsegmental pulmonary embolism managed without anticoagulation: a multicenter prospective cohort study

.

Ann Intern Med

.

2022

;

175

(

1

):

29

-

35

.

54.

Galanaud

JP

,

Trujillo-Santos

J

,

Bikdeli

B

, et al;

RIETE Investigators. Clinical presentation and outcomes of patients with cancer-associated isolated distal deep vein thrombosis

.

J Clin Oncol

.

2024

;

42

(

5

):

529

-

537

.

55.

Mahajan

A

,

Brunson

A

,

Eldredge

J

,

White

RH

,

Keegan

THM

,

Wun

T.

Incidence and outcomes associated with 6,841 isolated distal deep vein thromboses in patients with 13 common cancers

.

Thromb Haemost

.

2022

;

122

(

8

):

1407

-

1414

.

56.

Girardi

L

,

Ciuffini

LA

,

Mai

V

, et al.

Risk of recurrent venous thromboembolism and bleeding in patients with acute isolated subsegmental pulmonary embolism

.

Thromb Res

.

July

2024

;

239

:

109037

.

57.

Ageno

W

,

Haas

S

,

Weitz

JI

, et al.

Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE Registry

.

Thromb Haemost

.

2019

;

119

(

8

):

1365

-

1372

.

58.

Balabhadra

S

,

Kuban

JD

,

Lee

S

, et al.

Association of inferior vena cava filter placement with rates of pulmonary embolism in patients with cancer and acute lower extremity deep venous thrombosis

.

JAMA Netw Open

.

2020

;

3

(

7

):

e2011079

.

59.

Quezada

A

,

Jiménez

D

,

Bikdeli

B

, et al;

RIETE Investigators

.

Outcomes after vena cava filter use in patients with cancer-associated venous thromboembolism and contraindications to anticoagulation

.

Thromb Haemost

.

2020

;

120

(

7

):

1035

-

1044

.